corona update mers
DESCRIPTION
BY: DR.SATTI MOH’D SALEH INFECTIOUS DISEASE PHYSICIAN MEDICAL DIRECTOR MEEQAT GENERAL HOSPITAL CBAHI INFECTION CONTROL MEMBERTRANSCRIPT
Middle East Respiratory Syndrome Coronavirus (MERS-CoV):
BY:DR.SATTI MOH’D SALEH
INFECTIOUS DISEASE PHYSICIANMEDICAL DIRECTOR
MEEQAT GENERAL HOSPITALCBAHI INFECTION CONTROL MEMBER
CORONA VIRUS
-CORONA DERIVED FROM LATIN ( MEANS
CROWN OR HALO) DUE TO SHORT SPIKE LIKE PROJECTIONS (HE)
-MERS CoV
6 NEW TYPE OF CORONA VIRUS
-2ND OF 4 SUB GROUP ALPHA- B-GAMA & DELTA
-RNA VIRUS
-ALPHA & BETA DESCEND FROM BAT GENE POOL
-DELTA & GAMA FROM AVIAN GENE POOL
NOVEL CORONA VIRUS
NOVEL CORONA VIRUS REPORTED ON 24/9/2012 BY DR. ALI MOHAMMAD ZAKI
-ISOLATED & IDENTIFIED FROM PATIENT
60 YEARS OLD WITH ACUTE PNEUMONEA & ARF
BY DR. ALI M. ZAKI -POSTED HIS FINDINGS
المصري صور مكتشف الطبيب زكي عليكورونا فيروس
vb.n4hr.com-
Replication of Coronavirus
MERS CoV
NAMED AS NOVEL CORONA VIRUS OR SAUDI’S SARS LIKE CORONA VIRUS
-INTERNATIONAL COMMITTEE ON
TOXONOMY OF VIRUS NAME IT AS MERS CoV
MERS Cases and Deaths,April 2012 - PresentCurrent as of September 13, 2013, 9:00 AM EDT
Countries Cases (Deaths)
France 2 (1)
Italy 3 (0)
Jordan 2 (2)
Qatar 5 (2)
Saudi Arabia 90 (44)
Tunisia 3 (1)
United Kingdom (UK) 3 (2)
United Arab Emirates (UAE) 6 (2)
Total 114 (54
Countries With Lab-Confirmed MERS CasesApril 2012 - Present
•France•Italy•Jordan•Kuwait•Oman•Qatar•Saudi Arabia•Tunisia•United Kingdom (UK)•United Arab Emirates (UAE)
Globally, from September 2012 to date, WHO has been informed of a total of 198 laboratory-confirmed cases of infection with MERS-CoV, including 84 deaths
-Total number reported are 148 case.-Total death is 61 deaths 41.2%
- Males are 80 and Females are 52 cases.
- Saudi 110 and Non Saudi were 22.- Cases with known animal contacts are
20 out of 132 = 17.8% .- Primary cases are 47 , 11 of them had
contacts with animals = 23.4%
Numbers Reported up-to-date
INTERNATIONAL ALARM FOR TWO REASONS:
VIRUS OFTEN DEADLY
NO CLEAR TREATMENT
SOURCE UNKNOWN
-SPECULATION
BAT VIRUSES
INTERMEDIATE HOST
CAMELS & OTHERS
MULTIPLE GEOGRAPHIC SITES (MULTIPLE ZOOTIC EVENTS)
COMMON SOURCE
SOURCE
-? AUSTRALIA, U AFRICAN BATS
TO MIDDLE EAST
SORCE
SOURCE
*KNOWN FACTS
-HAS TROPISM TO NON CILIATED BROCHIAL EPITHELIAL CELLS (CONTRA TO OTHER VIRUSES
-CELLS THAT MERS INFECT WITHIN THE
LUNGS FORM 20 % OF RESPIRATORY EPITHELIAL CELLS
-LARGE NUMBER OF VIRUSES NEEDED
TO BE INHALED TO CAUSE INFECTION
Is this virus the same as the SARS virus?
No. The novel coronavirus is not the same virus that caused severe acute respiratory syndrome (SARS) in 2003. However, like the SARS virus, the novel coronavirus is most similar to those found in bats. CDC is still learning about this new virus.
Location of Bat Sampling Sites
A- Ghana B-
Europe
MERS-CoV INCUBATION period
The available data suggest that symptoms have occurred up to 14 days after last exposure .
SYMPTOMS:FeverCoughChillsSore throatMyalgiaArthralgia followed by dyspneaMay present with fever and diarrheaFollowed by ARDS, septic shock, multiorgan failure
MERS-CoV CLINICAL CASE definition
A person with an acute respiratory infection, which may include fever (≥ 38°C , 100.4°F) and cough; AND
Suspicion of pulmonary parenchymal disease (e.g., pneumonia or acute respiratory distress syndrome based on clinical or radiological evidence); AND
History of travel from the Arabian Peninsula or neighboring countries* within 14 days .
CDC Case Definitions :
Probable Case •Any person who -
–meets the criteria above for “Patient Under Investigation” and has clinical, radiological, or histopathological evidence of pulmonary parenchyma disease (e.g. pneumonia or ARDS), but no possibility of laboratory confirmation exists, either because the patient or samples are not available or there is no testing available for other respiratory infections, AND
–is a close contact with a laboratory-confirmed case, AND –has illness not already explained by any other infection or
etiology, including all clinically indicated tests for community-acquired pneumonia according to local management guidelines .
•OR any person with -–severe acute respiratory illness with no known etiology,
AND –an epidemiologic link to a confirmed MERS case .
.
Confirmed Case
•A person with laboratory confirmation of infection with MERS-CoV
Positive PCR for confirmation
Confirmed cases of MERS-CoV (n=55) and history of travel from the Arabian Peninsula
Check for co – infection with other viruses e.g.: H1N1, bacterial infection, fungal infection.
MERS-CoV CLOSE CONTACT definition
A close contact* is defined as a person who : Did not use respiratory protection (N95 or
higher level respirator); AND Shared the same airspace within 10 feet for
at least 5 minutes. Examples of close contact include providing care for the case (e.g., a healthcare worker or family member), or having similar close physical contact; or stayed at the same place (e.g., lived with, visited) as the case during their infectious period .
First Reported MERS-CoV Case
60 year old Saudi man •Presented on June 13th with 7d h/o fever
and cough; recent shortness of breath •Increasing blood urea nitrogen (BUN) and
creatinine, starting day 3 of admission •White cell count normal on admission
(but 92.5% neutrophils) and increased to a peak of 23,800 cells per cubic millimeter on day 10 with neutrophilia, lymphopenia, and progressive thrombocytopenia
First Case: Chest Radiographs
Bilateral enhanced pulmonary hilar vascular shadows (more prominent on the left) and accentuated bronchovascular lung markings. Multiple patchy opacities in middle and lower lung fields Opacities more confluent and dense
A: On admission
B: 2 days later
Radiographs of Patient 2
B. 4 days after onset of illness, Ground glass opacity and consolidation of left lower lobe
.Consolidation of right upper lobe, 1 day after onset of illness
C and D. Bilateral ground-glass opacities and consolidation, 7 days and 9 days after onset of illness, respectively
First Case Outcome
•Patient developed acute respiratory distress syndrome (ARDS) and multiorgan dysfunction syndrome
•Died June 24th •No close contacts with severe
illnesses reported
Saudi Arabia Household Cluster
•A cluster of 4 respiratory illnesses in a family who lived in an apartment
–All males; ages 16-70y •All hospitalized
•3 of 4 confirmed with MERS-CoV •3 of 4 patients with gastrointestinal
symptoms: diarrhea, abdominal pain, anorexia )
•2 deaths
Types of clusters
1 )Older clusters post alhassa (contained) are in Eastren, Hasa, Aseer and Riyadh.
2 )Resent Clusters started August, 17-12-/2013 (Almadina, Riyadh (hospitals), Hafralbatin)
MERS-CoV Outbreak in Saudi Arabia April – May 2013
•Al-Ahsa governorate in eastern region •Cluster currently being investigated
•25 confirmed cases, 14 confirmed deaths •18 males, 7 females; Ages 14 - 94 years, median
age: 58 •Initial cases associated with one hospital but
now also :–Family contacts
–Healthcare workers –Cases with no link to hospital
•Most cases with comorbidities
MERS CoV positive cases by sex and Nationalitya
Male Female Saudi Non Saudi0
20
40
60
80
100
120
80
52
110
22
MERS CoV positive cases by sex and Nationality
Male Female Saudi Non Saudi0
20
40
60
80
100
120
80
52
110
22
Al-Madina AlMunawara cluster
Resident 55
Dialysis (1)
Date of Onset
17/8/2013
Male 56 date of
18/8/2013
HCW
74 years old male on HD
Dead case
Alive
35 y on HD 89 y
54 y F
39 y M
HCW
Hafr Albatin cluster
3 cases asymptomatic Age 26,16,7
2 cases asymptomatic Age 3 and 18
38 y of age male (son)
8/8/2013
79 y mother
Cousin 47 y 23/8/2013
74 Mother the above
Dead caseAlive
MERS CoV cases by contact with animals and chronic disease total (111 cases) contact with animals 19
admitted animal contact no animal contact
chronic diseaseno disease
0
10
20
30
40
50
60
70
80
90
100
19
9288
23
-Camel 10 -Goat 2 ,
-Cat 2 , -Chicken 2 ,
- Bat 2,
- Others 1
It is not always possible to identify patients with MERS-CoV early because some have mild or unusual symptoms. For this reason, it is important that health-care workers apply standard precautions consistently with all patients – regardless of their diagnosis – in all work practices all the time.
Reported up-to-date
Droplet precautions should be added to the standard precautions when providing care to all patients with symptoms of acute respiratory infection. Contact precautions and eye protection should be added when caring for probable or confirmed cases of MERS-CoV infection. Airborne precautions should be applied when performing aerosol generating procedures .
precautionsReported up-to-
date
HAND HYAGIENEة
Gloves
•Gowns •Eye protection (goggles
or face shield) •Respiratory protection
that is at least as protective as a fit-tested NIOSH-certified disposable N95 filtering face piece respirator
Personal Protective Equipment (PPE) for Healthcare personnel (HCP)
Recommended PPE should be worn by HCP upon entry into patient rooms or care areas .
•Upon exit from the patient room or care area, PPE should be removed and either :
–Discarded, or –For re-useable PPE, cleaned and
disinfected according to the manufacturer’s reprocessing instructions .
Environmental Infection Control
•Follow standard procedures, per hospital policy and manufacturers’ instructions, for cleaning and/or disinfection of :
–Environmental surfaces and equipment
–Textiles and laundry –Food utensils and dishware
Infection Control Recommendations for Hospitalized Patients
•These recommendations are for hospitalized patients who meet the case definition and are based on the following issues :
–Poorly characterized clinical signs and symptoms, and a suspected high rate of morbidity and mortality among infected patients
–Unknown modes of transmission of MERS-CoV
–Lack of a vaccine and chemoprophylaxis –Evidence of limited, not sustained,
human-to-human transmission
Patient Placement Airborne Infection Isolation Room (AIIR)
–If an AIIR is not available, the patient should be transferred as soon as is feasible to a facility where an AIIR is available .
–Pending transfer, place a facemask on the patient and isolate him/her in a single-patient room with the door closed .
–The patient should not be placed in any room where room exhaust is recirculated without high-efficiency particulate air (HEPA) filtration .
•Once in an AIIR, the patient’s facemask may be removed .
•When outside of the AIIR, patients should wear a facemask to contain secretions .
Patient Placement
Limit transport and movement of the patient outside of the AIIR to medically-essential purposes .
•Implement staffing policies to minimize the number of personnel who must enter the room .
Health-care providers are advised to maintain vigilance .
-NO SUSTAINED TRANSMISSION IN
COMMUNITY
-PEOPLE WITH COMORBIDITY OR IMMUNOSUPPRESSION
INCREASE INFECTION ,INCREASE COMPLICATION,
INCREASE MORBIDITY
PERSON TO PERSON TRANSMISSION (VERY LOW)
People at high risk
of severe disease due to MERS-CoV should avoid close contact with animals when visiting farms or barn areas where the virus is known to be potentially circulating. For the general public, when visiting a farm or a barn, general hygiene measures, such as regular hand washing before and after touching animals, avoiding contact with sick animals, and following food hygiene practices, should be adhered to.
Complications
Complications have included severe 1 -pneumonia, acute respiratory distress
syndrome 2- (ARDS) with multi-organ failure,
3 -renal failure requiring dialysis, consumptive 4- coagulopathy and
pericarditis .
The number of people who came for Umra this year 1434 – 2013 are:
5,138,301NO cases
Umra statistics During
1434
ADVISES IN HAJJ & UMRA
FREQUENT HAND WASHING CONTACT WITH OTHERS
NOT TO TOUCH EYE NOSE & MOUTH WITHOUT HAND WASHING
COVER MOUTH, NOSE WITH TISSUES (NOT TO INFECT OTHERS ON COUGHING & SNEEZING)
CDC does not recommend that travelers change their plans because of MERS. However, the Saudi Arabia Ministry of Health has made special recommendations for travelers to Hajj and Umrah. Because of the risk of MERS, Saudi Arabia recommends that the following groups should postpone their plans for Hajj and Umrah this year:People over 65 years oldChildren under 12 years oldPregnant womenPeople with chronic diseases (such as heart disease, kidney disease, diabetes, or respiratory disease)People with weakened immune systemsPeople with cancer or terminal illnessesCDC encourages people traveling to Saudi Arabia to perform Hajj or Umrah to consider this advice. People who are concerned about MERS should discuss their travel plans with their doctor.
How Can Travelers Protect Themselves?
Taking these everyday actions can help prevent the spread of germs and protect against colds, flu, and other illnesses:Wash your hands often with soap and water. If soap and water are not available, use an
- alcohol based hand sanitizer.Avoid touching your eyes, nose, and mouth. Germs spread this way.Avoid close contact with sick people.Be sure you are up-to-date with all of your shots, and if possible, see your healthcare provider at least 4–6 weeks before travel to get any additional shots.
.If you are sick:Cover your mouth with a tissue when you cough or sneeze, and throw the tissue in the trash.Avoid contact with other people to keep from infecting them.
Investigations
Chest x – ray findings:
Bilateral hailer infiltrate Bilateral patchy infiltrate Segmental or lobar opacity Pleural effusion
Laboratory Testing Lower respiratory specimens
(sputum, bronchoalveolar lavage, endotracheal) are a priority respiratory specimen for real time reverse transcription polymerase chain reaction (RT-PCR) testing
•Respiratory (lower and upper tracts), stool, and
serum specimens •Specimen collection at different
times
Positive PCR for confirmation
Emergency Use Authorization
•FDA issued an EUA on June 5, 2013, to authorize use of CDC's “Novel coronavirus 2012 real-time reverse transcription–PCR assay” to test for MERS-CoV in clinical respiratory, blood, and stool specimens .
•Assay will be deployed to Laboratory Response Network (LRN) laboratories in all 50 states over the coming weeks .
Approach to Serology
•Identify and generate candidate CoV antigens
–Using proteins from similar bat viruses •Develop ELISA-based assay
•Evaluate assay with an extensive panel of negative (specificity) and positive sera (sensitivity)
Therapeutics
•No vaccines developed as of yet
•antivirals identified as of yet •Treatment
USED IN MONKEY-
SYMPTOMS, SLOW VIRAL GROWTH DAMAGE TO LUNGS, BREATHING
(ONLY USED IN FEW MONKEYS WITHIN 8 HOURS OF INFECTIONS)
USED
I
N
MONKEY
Management:
Isolation: standard + droplet
±airborne precautions Organ support Prevention of complications
Empiric use of:
Broad spectrum antibiotic Antiviral (oseltamivir) Plus or minus antifungal Lung protective ventilator Strategies for ARDS Treatment of complication (RENAL
FAILURE) Steroids (no benefits) Treatment of HCAI
IF YOU HAVE A DYING PATIENT SHOULD ,
؟؟YOU TRY IT AS LAST EFFORT
FUTURE TREATMENT
INTERFERON ALFA 2 + RIBAVERIN
USED IN MONKEY-
SYMPTOMS, SLOW VIRAL GROWTH DAMAGE TO LUNGS, BREATHING
(ONLY USED IN FEW MONKEYS WITHIN 8 HOURS OF INFECTIONS)
USED
I
N
MONKEY
Selection criteria:
To be considered eligible for oral ribavirin and subcutaneous pegylated interferon therapy, the patient
must fulfill ALL the following criteria:
1. Laboratory-confirmed MERS-CoV infection
2. Clinical and radiological evidence of pneumonia
3. The patient requires invasive or non-invasive ventilatory support or showing progressive
hypoxemia
4. Approval by one consultants in Adult Infectious Diseases
Administration Protocol:
CrCl‡ > 50ml/min Ribavirin 2000mg po loading dose, followed by 1200mg po q8h for 4 days then 600mg po q8h for 4-6 days
CrCl 20-50 ml/min
2000mg po loading dose, followed by 600mg po q8h for 4 days then 200mg po q6h for 4-6 days
CrCl <20 ml/min or on dialysis
2000mg po loading dose, followed by 200mg po q6h for 4 days then 200mg po q12h for 4-6 days
Pegelated interferon
Pegelated interferon alfa 2a 180 mcg subcutaneously once per week
(up to 2 weeks)
Monitoring :
1. Both ribavirin and Peg-interferon are associated with considerable potential adverse effects. In
addition to any clinical or laboratory monitoring that is dictated by the patient’s condition, the
following investigations are essential before starting
a. Complete blood count b. Renal function c. Liver function
2. Conscious patients must have a formal psychiatric assessment if there is any clinical evidence
of psychosis or acute confusion Changes to the treatment protocol: 1. Changes in the treatment
protocol in response to toxicity or clinical developments are permitted. A
psychiatric assessment
LAST REMINDER, NO UNNECESSARY PANIC…
ALWAYS COMPLY WITH INFECTION CONTROL & PREVENTION STANDARDS
الفاشيات
متفرقة( 1 احادية تكون ان يمكن الحاالت (Sporadic.)تم( 2 حيث فاشيات شكل في تكون ان يمكن الحاالت
- – - الرياض الشرقية االحساء في فاشيات عدة رصدالمنورة – المدينة عسير
بمجهودات وذلك جميعا عليها السيطرة تم الله وبحمدوالمختبرات والمناطق الوزارة ديوان في العاملين
بالمستشفيات العدوى مكافحة قواعد اتباع تم حيثالوقائية والجراءات بالمنزل المخالطين وتوعية
. العامة الصحة وكالة اتخذتها التي االخرى
SUMMARY ●According to the investigations made for the 148
cases we do not know the source of the infection ( possible animal? Camels, Possible human.. GOK
●Human transmission is there we do not know how? Possible close contact or droplet???
●Chronic disease is a risk factor specially kidney disease.
●Serological investigation are not yet done but samples are available for testing.
●we will continue surveillance and research.
ما قامت به وزارة الصحة
الوباء ( 2 هذا لمواجهة مفصلة خطة بإعداد الوزارة قامتبالنسبة الوقاية وطرق االجرائية الخطوات على والمرتكزة
وتم بالمنزل للمرضى المخالطين الى باإلضافة الصحيين للعامليناالعالم وسائل تزويد تم كما الصحية المنشآت جميع على توزيعها
بذلك.
المرافق( 3 جميع الى بالنماذج مدعم شامل تعميم اصدار تمتحديث وتم المشتبهة الحاالت عن لالبالغ بالمملكة الصحية
. للمرض المستجدات ليواكب مرات عدة التعميم
ما قامت به وزارة الصحة
أطباء( 1 تضم المعدية لألمراض علمية وطنية لجنة وجودوطب العامة والصحة المعدية االمراض في استشاريونبالمملكة الصحية القطاعات جميع من والمجتمع االسرة
والداخلية ) الدفاع بوزارات والطبية الصحية الخدمات يمثلون ) فيصل الملك ومستشفى والتعليم والتربية الوطني والحرسالطب كلية في ممثلة والجامعات االبحاث ومركز التخصصيمع السعودية أرامكو ومستشفى سعود الملك بجامعة
للصحة الصحة وزارة وكيل وبرئاسة الصحة وزارة استشارييواللجنة الوقائي العامة العمل سياسات وضع ومهامها
وتحديثها الكورونا التهاب ومنها األهمية ذات المعدية لألمراضدوريا́.